Background. Our aim was to quantify human involuntary isometric skeletal muscle strength during anaesthesia with propofol, sevo¯urane, or spinal anaesthesia using bupivacaine.
Anaesthetics in¯uence voltage-gated ion channels in the nervous system as well as in skeletal and cardiac muscle. By enhancing sodium current decay in the muscle cell they change signal transduction and may have neuromuscular blocking agent properties; propofol, local anaesthetics, and inhaled anaesthetics have this ability. 1 2 Moreover, anaesthetic agents may alter contractile function by inhibition of cholinergic neurotransmission. 3 Such altered activities could in¯uence recovery from anaesthesia.
To determine muscle strength, isometric assessment tools have to be distinguished from dynamic tools. The measured values are strongly in¯uenced by an investigator's experience and the patient's voluntary efforts, so results are not always objective and reproducible. 4 To improve objectivity, ®xed devices have been developed. By using electrical nerve stimulation and electronic data acquisition, it is now possible to get quantitative, non-invasive muscle force assessment results, independent of a subject's voluntary efforts.
with bupivacaine on human involuntary isometric skeletal muscle strength following electrical stimulation.
Methods
Before and during anaesthesia, the involuntary isometric skeletal muscle strength of the ankle dorsi¯exor muscles after peroneal nerve stimulation in humans was investigated.
Patients
All 33 patients gave their written informed consent, and the Human Ethics Committee of the University of Basel, Switzerland approved the experimental protocol. All patients were ASA I and were to undergo orthopaedic or venous surgery to the lower limb. The patients chose whether to receive either spinal anaesthesia or general anaesthesia. Those patients who chose to receive general anaesthesia were allocated randomly to receive either propofol or sevo¯urane for induction and maintenance of anaesthesia.
Muscle force assessment system
For nerve stimulation, a Grass S11 stimulator (Grass Medical Instruments, Quincy, MA) was used. A special device that securely held the subject's leg was used for quanti®cation of muscle torque (Fig. 1) . 5±8 The torque was measured by a strain gauge (SG-2/350-LY41 Strain Gauges, OMEGA Engineering, Inc., Stamford, CT) attached to an aluminium bar that restrained movement of the footplate. The output of the strain gauge was ampli®ed (ampli®er: Grass Medical Instruments); voltage changes proportional to the muscle torque were digitized through a data acquisition card (DAQCardÔ-1200, National Instruments, Austin, TX), converted into force and then stored on a personal computer. All data acquisition and analysis programs were written with LabVIEW 2 (National Instruments, Austin, TX).
Experimental protocol
All patients received midazolam 0.1 mg kg ±1 orally 1 h before the experiments. A sample of blood was analysed for Na
2+ , phosphate, urea, creatine kinase, glucose, and haemoglobin concentrations, and a coagulation screen was done. The circumference and skin fold thickness of the lower leg were measured.
After arrival in the operating theatre, an i.v. catheter was sited and an infusion of Ringer lactate solution (500 ml) was started. Standard monitoring was attached and a surface temperature probe was used to determine the temperature over the tibialis anterior muscle (GeniusÔ, infrared thermometer, Sherwood-Davis & Geck, Gosport, UK): for patients receiving general anaesthesia, the Bispectral IndexÔ was monitored also.
The muscle force assessment system was attached to each patient as follows: the patient was laid on the surgical table with one leg strapped in a stabilizing device that was ®tted with a force measuring boot into which the foot was placed. A convective warm-air system was used to minimize variability in dorsi¯exor muscle temperature; the skin temperature of the leg was maintained between 31 and 32°C. After cleaning the skin with an alcoholic wipe, a pair of small ball-shaped electrodes was pressed tightly against the skin behind the head of the ®bula for transcutaneous common peroneal nerve stimulation. An electromyogram (EMG) of the tibialis anterior muscle was recorded with surface patch electrodes. 10 The supramaximal voltage (approximately 50±90 V with 0.3 ms duration) was used for stimulation and this was determined by increasing the voltage until no further increases in muscle twitch torque and in the EMG signal of the ankle dorsi¯exors were detected. The optimal muscle length for isometric contraction (in this case, the ankle joint position) was determined by moving the torque plate until twitch torques reached a maximum. 9 This position of the torque plate was then ®xed and kept unchanged during the experiment. Baseline measurements were then performed. The protocol included single, double, triple, and quadruplepulse peroneal nerve stimulation. 5±8 These were unidirectional depolarizing pulse stimuli with a pulse duration of 0.3 ms. The pulse interval for the multiple pulse stimula- 5±8 It is composed of four main components: (i) a stabilizing device consisting of two metal bars, straps and a boot. The boot is ®xed on a foot plate that can be rotated and ®xed at any position between ±40 and 40°. (ii) A strain gauge system with a Wheatstone bridge circuit that detects the evoked torque produced by the stimulated ankle dorsi¯exor muscles. (iii) A stimulator/ampli®er unit that can supply variable stimulus pulse amplitudes and pulse durations and can amplify the voltage changes, evoked by the torque of the stimulated muscle. (iv) A computer with data acquisition software for recording, analysing and displaying all signals simultaneously. tions was 5 ms. Between each set of stimuli there was a 2 min rest period. After baseline measurements were ®nished, general or spinal anaesthesia was administered.
One of two general anaesthetic regimens was used: (i) a target controlled infusion (TCI) of propofol with the target concentration set at 5 mg ml ±1 ; (ii) inhalation induction with sevo¯urane 6±8 vol%, in oxygen 100%, followed by maintenance with sevo¯urane at an end-tidal concentration of 3±3.5 vol%. A laryngeal mask was used in both groups for airway maintenance and ventilation of the lungs was controlled to keep the EE¢ CO 2 at 4.5±5 kPa. After a 20 min stabilization period, the measurements were repeated. During this measurement period, the Bispectral IndexÔ was between 40 and 50. In the propofol group, blood was taken and the plasma obtained was used to determine the concentration of propofol by high performance liquid chromatography with¯uorescence detection.
Spinal anaesthesia was performed with hyperbaric bupivacaine 0.5%, 0.2 mg kg ±1 . When a stable sensory level was reached (upper level between the 6th and 9th thoracic dermatome), the second set of measurements was performed. Completion of both sets of measurements took about 1 h for each subject.
Data analysis
The following indices of isometric skeletal muscle performance were determined: (i) peak torque (Nm): the maximum amount of developed involuntary isometric muscle torque; (ii) contraction time (ms): time from the onset of torque development to peak torque; (iii) halfrelaxation time (ms): time for the torque to decay from its peak to 50% of peak torque; (iv) peak rate of torque development (Nm s ±1 ): the maximum rate (®rst derivative) of torque development; (v) peak rate of torque decay (Nm s ±1 ): the maximum rate of torque decay; (vi) time to peak torque development (ms): the time from the onset of torque development to the peak rate of torque development; (vii) time to peak torque decay (ms): the time from the peak rate of torque development to the peak rate of torque decay; (viii) torque latency (ms): the time from the stimulus to the onset of torque development (Fig. 2) .
Statistical analysis
The StatView program (ADEPT â , Hertfordshire, UK) was used. Pre-anaesthetic and anaesthetic muscle force measurements for each group were compared with the Wilcoxon signed rank test. The values between the different anaesthetic groups were analysed with the Kruskal±Wallis test. Measurements in men and women were compared with the Mann±Whitney rank-sum test. P-values <0.05 were considered to be signi®cant.
Results
Thirty-three patients were recruited and their characteristics are shown in Table 1 . A total of 376 measurements were performed. The same physician performed the measurements for all patients.
The within-session test±retest reliability for peak torque was 6%. The peak torque development (for all stimulus protocols combined) of male patients from all groups combined was greater than that of female patients, medians 6.3 (range 1.2±24.9) vs 4.4 (0.8±12.0) Nm, respectively (P=0.0002, Mann-Whitney rank-sum test). Male patients also had a greater peak torque development during anaesthesia, 8.9 (range 0.5±25.9) vs 5.0 (0.5±18.0) Nm (P<0.0001).
During spinal anaesthesia, peak torque values were diminished for single-and double-pulse stimulation but not for the other stimulation modalities ( Table 2 ). The peak rates of torque development decreased for single-and double-pulse stimulation and the torque latency period for single-pulse stimulation only was increased (Table 2) .
During spinal anaesthesia with bupivacaine, the peak torque values for single-and double-pulse stimulation were decreased compared with the corresponding values from the groups treated with propofol or sevo¯urane (see Table 2 ). In the propofol and sevo¯urane groups, pre-anaesthetic and anaesthetic values were not signi®cantly different (Wilcoxon signed rank test, Table 2 ).
Discussion
We have demonstrated that clinical concentrations of propofol or sevo¯urane did not in¯uence isometric skeletal muscle strength in healthy adults, but spinal anaesthesia did have a small effect.
Propofol blocks voltage-gated channels and thus has a neuromuscular blocking agent effect. This occurs especially in pathological conditions that result in a higher fraction of inactivated channels, such as hypoxia, myotonia, or Skeletal muscle strength during anaesthesia ischaemia. 11 12 Thus, propofol might be the drug of choice for induction of anaesthesia in patients with myotonia. Propofol also exerts a direct negative inotropic effect on failing and non-failing human myocardium, although only at concentrations exceeding the clinical-dose range. 13 Volatile anaesthetics inhibit skeletal muscle sodium channels. Mountsey and colleagues describe a dose-dependent enhancement of the rate of sodium current decay and a small reduction in sodium current amplitude in rat skeletal muscle for halothane. 1 In animals, the compound muscle action potentials are signi®cantly lower during application of volatile anaesthetics. 14 15 Bouhemad and colleagues describe a moderate negative inotropic effect in rat diaphragm muscle in vitro during application of iso¯urane (at 2Q MAC). 16 In an in vitro study using animal tissue, sevo¯urane did not enhance the reduction of tension induced by diaphragmatic fatigue but enhanced the prolongation of contraction time and half-relaxation time. 17 Halothane causes a decreased calcium sensitivity and decreased isometric tension in human type I, but not type II skeletal muscle ®bres. 18 On the other hand, there is an increased maximal skeletal muscle Ca 2+ -activated force in the presence of volatile anaesthetics. 19 Moreover, volatile anaesthetics have a direct action on neuromuscular transmission. 3 20 Thus, the effects on striated muscles remain controversial.
We found no in¯uences of sevo¯urane or propofol on human isometric skeletal muscle strength in vivo. The short- 8 (7) 9 (7) 12 (11) Plasma propofol concentration (mg ml ±1 ) 3.9 (0.7) ± ± Dose of bupivacaine (mg) ± ± 15 (3) End-tidal sevo¯urane concentration (vol%) ± 3.6 (0.6) ± term effect-site equilibration time of propofol and its high drug transfer rate to the peripheral compartment enable us to assume that propofol concentrations in skeletal muscle and plasma were similar. The plasma concentration of propofol was in the range of the half-maximum blocking concentration of skeletal muscle sodium channels; thus, the effects were too small to be measured in our clinical setting. 11 21 Since volatile agents reduce isometric force values by about 10% of baseline values in vitro, 16 their effects again could have been too small to be measured in vivo. Moreover effects of volatile agents are supposed to be more pronounced during muscle fatigue. 17 The distribution of muscle ®bre types with their different susceptibility towards volatile anaesthetics can also vary between subjects. 22 Spinal anaesthesia blocks the roots of the nerve ®bres and the super®cial layers of the spinal cord. 23 This results in ā accid paralysis of the muscles and block of the sympathetic out¯ow. Whereas the main part of this central sympathetic out¯ow innervates organs such as the heart, lungs, sweat glands, and skin, only a minor component reaches the skeletal muscle and has no measurable in¯uence on muscle tone, as was demonstrated by Smith during spinal anaesthesia. 24 Moreover, during static exercise in humans, central command was found to contribute very little to the activation of sympathetic out¯ow in skeletal muscle. 25 However, peripheral afferent impulses from muscle mechanoreceptors (muscle spindles), Golgi tendon organs, and chemosensitive endings in muscles in¯uence sympathetic nerve activity and skeletal muscle tension by re¯ex mechanisms. During static handgrip, an increased sympathetic discharge to muscle was measured, and muscle sympathetic nerve activity returned to control values during relaxation. 26 27 Electrically evoked involuntary biceps exion also results in increased muscle sympathetic nerve activity. 26 During spinal anaesthesia, these afferent impulses are blocked, which could explain the lower values for evoked torque and peak rate development. Direct actions of local anaesthetics on the pre-synaptic, post-junctional, and muscle membranes are only relevant for i.v. application with a moderate to high drug-plasma level and not for spinal application, thus excluding this effect from contributing to our ®ndings. 28 The following points must be considered when assessing the relevance of our results. First, for a complete assessment of muscle function it is desirable to study strength variables on the load continuum from isotonic (with low loads) to isometric (with high loads) conditions. In our setting, only isometric measurements were performed. However, negative inotropic effects of anaesthetics typically are found under isometric and not isotonic conditions. 16 Secondly, completely standardized conditions are only possible in in vitro studies; for example, inter-subject variability in perfusion, tissue temperature, and muscle cross-sectional area may have in¯uenced the test results. However, clinical trials are required to con®rm in vitro results under clinical conditions and such variability can be minimized using appropriate study groups.
Our study is the ®rst to use the described muscle-force assessment system during anaesthesia. This new system made it possible to obtain objective and reliable results, independent of a subject's voluntary effort. 5±8 The system is versatile, enabling the examination of different muscle groups. 7 Thus, we recommend such a system to investigate skeletal muscle strength, for example, in patients with potential muscle atrophy, critical illness polyneuropathy, or myopathy.
In conclusion, we evaluated the isometric skeletal muscle strength of the lower leg under different anaesthetic regimens in humans. At clinically relevant concentrations, neither sevo¯urane nor propofol changed muscle strength, whereas during spinal anaesthesia there was a small impairment of strength. The skeletal neuromuscular blocking agent properties of anaesthetics do not seem to have a profound effect on isometric skeletal muscle strength in humans in vivo.
